IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature MedicineGlobeNewsWire • 12/09/21
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket TrialGlobeNewsWire • 12/06/21
IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 11/09/21